{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:22:20Z","timestamp":1781968940483,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous reports suggest septal hypertrophy with an interventricular septum depth (IVSD)\u2009\u2265\u200914\u00a0mm may adversely affect outcomes after transcatheter aortic valve implantation (TAVI) due to suboptimal valve placement, valve migration, or residual increased\u00a0LVOT\u00a0pressure gradients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>This analysis investigates the impact of interventricular septal hypertrophy on acute outcomes after TAVI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between 2009 and 2021, 1033 consecutive patients (55.8% male, 80.5\u2009\u00b1\u20096.7\u00a0years, EuroSCORE II 6.3\u2009\u00b1\u20096.5%) with documented IVSD underwent TAVI at our center and were included for analysis. Baseline, periprocedural, and 30-day outcome parameters of patients with normal IVSD (&lt;\u200914\u00a0mm; group 1) and increased IVSD (\u2265\u200914\u00a0mm; group 2) were compared. Data were retrospectively analyzed according to updated Valve Academic Research Consortium-3 (VARC-3) definitions. Comparison of outcome parameters was adjusted for baseline differences between groups using logistic and linear regression analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 1033 patients, 585 and 448 patients were allocated to groups 1 and 2, respectively. There was no significant difference between groups regarding transfemoral access rate (82.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009478) vs. 86.0% (<jats:italic>n<\/jats:italic>\u2009=\u2009381), <jats:italic>p<\/jats:italic>\u2009=\u20090.157). Postprocedural mean transvalvular pressure gradient was significantly increased in group 2 (group 1, 7.8\u2009\u00b1\u20094.1\u00a0mmHg, vs. group 2, 8.9\u2009\u00b1\u20094.9\u00a0mmHg, <jats:italic>p<\/jats:italic>\u2009=\u20090.046). Despite this finding, there was no significant difference between groups regarding the rates of VARC-3 adjudicated composite endpoint device success (90.0% (<jats:italic>n<\/jats:italic>\u2009=\u2009522) vs. 87.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009388), <jats:italic>p<\/jats:italic>\u2009=\u20090.538) or technical success (92.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009542) vs. 92.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009415), <jats:italic>p<\/jats:italic>\u2009=\u20090.639). Moreover, the groups showed no significant differences regarding the rates of paravalvular leakage\u2009\u2265\u2009moderate (3.1% (<jats:italic>n<\/jats:italic>\u2009=\u200914) vs. 2.6% (<jats:italic>n<\/jats:italic>\u2009=\u20099), <jats:italic>p<\/jats:italic>\u2009=\u20090.993), postprocedural permanent pacemaker implantation (13.4% (<jats:italic>n<\/jats:italic>\u2009=\u200977) vs. 13.8% (<jats:italic>n<\/jats:italic>\u2009=\u200961), <jats:italic>p<\/jats:italic>\u2009=\u20090.778), or 30-day mortality (5.1% (<jats:italic>n<\/jats:italic>\u2009=\u200930) vs. 4.5% (<jats:italic>n<\/jats:italic>\u2009=\u200920), <jats:italic>p<\/jats:italic>\u2009=\u20090.758).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Although transvalvular mean pressure gradients were significantly higher in patients with increased IVSD after TAVI, acute outcomes were comparable between groups suggesting no early impact of adverse hemodynamics due to elevated IVSD. However, how these differences in hemodynamic findings may affect mid- and long-term outcomes, especially in terms of valve durability, needs to be evaluated in further investigations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00392-024-02432-3","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T09:01:32Z","timestamp":1710147692000},"page":"332-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transcatheter aortic valve implantation in patients with significant septal hypertrophy"],"prefix":"10.1007","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0925-7067","authenticated-orcid":false,"given":"Martin","family":"Beyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till Joscha","family":"Demal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Bhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Voigtlaender-Buschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Reichenspurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenard","family":"Conradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"2432_CR1","first-page":"e35","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O\u2019Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C (2021) 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 143:e35-71","journal-title":"Circulation"},{"key":"2432_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, J\u00fcni P, Pierard L, Prendergast BD, S\u00e1daba JR, Tribouilloy C, Wojakowski W, ESC\/EACTS Scientific Document Group, ESC National Cardiac Societies (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 43:561\u2013632","journal-title":"Eur Heart J"},{"key":"2432_CR3","doi-asserted-by":"publisher","first-page":"e027705","DOI":"10.1161\/JAHA.122.027705","volume":"11","author":"MP S\u00e1","year":"2022","unstructured":"S\u00e1 MP, Erten O, Ramlawi B (2022) Transcatheter aortic valve implantation in elderly patients with aortic valve stenosis: the role of frailty, malnutrition, and sarcopenia. J Am Heart Assoc 11:e027705","journal-title":"J Am Heart Assoc"},{"key":"2432_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.amjcard.2017.07.060","volume":"120","author":"E Regev","year":"2017","unstructured":"Regev E, Finkelstein A, Assali A, Barbash I, Fefer P, Ben-Shoshan J, Orvin K, Konigstein M, Guetta V, Kornowski R, Segev A (2017) Comparison of outcome of transcatheter aortic valve implantation for severe aortic stenosis in 3 age groups (\u226470; 71 to 80, and \u226581 years). Am J Cardiol 120:1607\u20131611","journal-title":"Am J Cardiol"},{"key":"2432_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00392-021-01968-y","volume":"111","author":"D Grundmann","year":"2022","unstructured":"Grundmann D, Linder M, Go\u00dfling A, Voigtl\u00e4nder L, Ludwig S, Waldschmidt L, Demal T, Bhadra OD, Sch\u00e4fer A, Schirmer J, Reichenspurner H, Blankenberg S, Westermann D, Schofer N, Conradi L, Seiffert M (2022) End-stage renal disease, calcification patterns and clinical outcomes after TAVI. Clin Res Cardiol 111:1313\u20131324","journal-title":"Clin Res Cardiol"},{"key":"2432_CR6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.amjcard.2017.08.020","volume":"120","author":"A Levi","year":"2017","unstructured":"Levi A, Codner P, Masalha A, Gargiulo G, Praz F, Hayashida K, Watanabe Y, Mylotte D, Debry N, Barbanti M, Lef\u00e8vre T, Modine T, Bosmans J, Windecker S, Barbash I, Sinning J-M, Nickenig G, Barsheshet A, Kornowski R (2017) Predictors of 1-year mortality after transcatheter aortic valve implantation in patients with and without advanced chronic kidney disease. Am J Cardiol 120:2025\u20132030","journal-title":"Am J Cardiol"},{"key":"2432_CR7","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.3390\/jcm11195580","volume":"11","author":"S Schoechlin","year":"2022","unstructured":"Schoechlin S, Eichenlaub M, M\u00fcller-Edenborn B, Neumann F-J, Arentz T, Westermann D, Jadidi A (2022) Risk stratification for pacemaker implantation after transcatheter aortic valve implantation in patients with right bundle branch block. J Clin Med 11:5580","journal-title":"J Clin Med"},{"key":"2432_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00392-018-1263-x","volume":"107","author":"A Schaefer","year":"2018","unstructured":"Schaefer A, Neumann N, Linder M, Schofer N, Schneeberger Y, Deuschl F, Schoen G, Blankenberg S, Reichenspurner H, Conradi L, Sch\u00e4fer U (2018) Outcomes with a latest generation self-expandable, intra-annular, re-sheathable transcatheter heart valve system: analysis of patients with impaired left ventricular function and determinants for pacemaker implantation. Clin Res Cardiol 107:914\u2013923","journal-title":"Clin Res Cardiol"},{"key":"2432_CR9","doi-asserted-by":"publisher","unstructured":"Wienemann H, Maier O, Beyer M, Portratz M, Tanaka T, Mauri V, Ernst A, Waldschmidt L, Kuhn E, Bleiziffer S, Wilde N, Schaefer A, Zeus T, Baldus S, Zimmer S, Veulemans V, Rudolph TK, Adam M (2023) Cusp overlap versus standard three-cusp technique for self-expanding Evolut transcatheter aortic valves. EuroIntervention 19(2):e176\u2013e187.\u00a0https:\/\/doi.org\/10.4244\/EIJ-D-22-01030","DOI":"10.4244\/EIJ-D-22-01030"},{"key":"2432_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1007\/s00392-022-02052-9","volume":"111","author":"V Veulemans","year":"2022","unstructured":"Veulemans V, Nuyens P, Goh S, Maier O, Binneb\u00f6\u00dfel S, Heermann J, Jung C, Westenfeld R, Kelm M, de Backer O, Zeus T (2022) Bioprosthetic valve dysfunction and failure after TAVI in bicuspid aortic valve stenosis during one-year follow-up according to VARC-3. Clin Res Cardiol 111:1358\u20131366","journal-title":"Clin Res Cardiol"},{"key":"2432_CR11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.echo.2019.06.012","volume":"32","author":"NJ Kiefer","year":"2019","unstructured":"Kiefer NJ, Salber GC, Burke GM, Chang JD, Guibone KA, Popma JJ, Hahn RT, Pinto DS, Strom JB (2019) The impact of basal septal hypertrophy on outcomes after transcatheter aortic valve replacement. J Am Soc Echocardiogr 32:1416\u20131425","journal-title":"J Am Soc Echocardiogr"},{"key":"2432_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/oxfordjournals.eurheartj.a062034","volume":"7","author":"LM Shapiro","year":"1986","unstructured":"Shapiro LM, Howat AP, Crean PA, Westgate CJ (1986) An echocardiographic study of localized subaortic hypertrophy. Eur Heart J 7:127\u2013132","journal-title":"Eur Heart J"},{"key":"2432_CR13","first-page":"316","volume":"9","author":"MA Kelshiker","year":"2013","unstructured":"Kelshiker MA, Mayet J, Unsworth B, Okonko DO (2013) Basal septal hypertrophy. Curr Cardiol Rev 9:316\u2013324","journal-title":"Curr Cardiol Rev"},{"key":"2432_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0300-8932(10)70046-4","volume":"63","author":"R Moreno","year":"2010","unstructured":"Moreno R, Calvo L, Garc\u00eda E, Dobarro D (2010) Severe septal hypertrophy: is it necessarily a contraindication for the transcatheter implantation of an Edwards-Sapien prosthesis? Rev Esp Cardiol 63:241\u2013242","journal-title":"Rev Esp Cardiol"},{"key":"2432_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1540-8175.2008.00806.x","volume":"26","author":"T Diaz","year":"2009","unstructured":"Diaz T, Pencina MJ, Benjamin EJ, Aragam J, Fuller DL, Pencina KM, Levy D, Vasan RS (2009) Prevalence, clinical correlates and prognosis of discrete upper septal thickening on echocardiography. Echocardiography 26:247\u2013253","journal-title":"Echocardiography"},{"key":"2432_CR16","doi-asserted-by":"publisher","first-page":"e1921669","DOI":"10.1001\/jamanetworkopen.2019.21669","volume":"3","author":"D Bandyopadhyay","year":"2020","unstructured":"Bandyopadhyay D, Chakraborty S, Amgai B, Kapadia SR, Braunwald E, Naidu SS, Kalra A (2020) Association of hypertrophic obstructive cardiomyopathy with outcomes following transcatheter aortic valve replacement. JAMA Netw Open 3:e1921669","journal-title":"JAMA Netw Open"},{"key":"2432_CR17","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","volume":"77","author":"P G\u00e9n\u00e9reux","year":"2021","unstructured":"VARC-3 WRITING COMMITTEE, G\u00e9n\u00e9reux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB (2021) Valve Academic Research Consortium 3: updated endpoint definitions for aortic\u00a0valve clinical research. J Am Coll Cardiol 77:2717\u201346","journal-title":"J Am Coll Cardiol"},{"key":"2432_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/01.CIR.55.3.489","volume":"55","author":"BJ Maron","year":"1977","unstructured":"Maron BJ, Clark CE, Henry WL, Fukuda T, Edwards JE, Mathews EC, Redwood DR, Epstein SE (1977) Prevalence and characteristics of disproportionate ventricular septal thickening in patients with acquired or congenital heart diseases: echocardiographic and morphologic findings. Circulation 55:489\u2013496","journal-title":"Circulation"},{"key":"2432_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0735-1097(83)80191-0","volume":"1","author":"OM Hess","year":"1983","unstructured":"Hess OM, Schneider J, Turina M, Carroll JD, Rothlin M, Krayenbuehl HP (1983) Asymmetric septal hypertrophy in patients with aortic stenosis: an adaptive mechanism or a coexistence of hypertrophic cardiomyopathy. J Am Coll Cardiol 1:783\u2013789","journal-title":"J Am Coll Cardiol"},{"key":"2432_CR20","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1161\/CIRCULATIONAHA.112.000470","volume":"128","author":"A Krishnaswamy","year":"2013","unstructured":"Krishnaswamy A, Tuzcu EM, Svensson LG, Kapadia SR (2013) Combined transcatheter aortic valve replacement and emergent alcohol septal ablation. Circulation 128:e366\u2013e368","journal-title":"Circulation"},{"key":"2432_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1161\/01.CIR.66.4.835","volume":"66","author":"JJ Bird","year":"1982","unstructured":"Bird JJ, Murgo JP, Pasipoularides A (1982) Fluid dynamics of aortic stenosis: subvalvular gradients without subvalvular obstruction. Circulation 66:835\u2013840","journal-title":"Circulation"},{"key":"2432_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jcin.2021.10.002","volume":"15","author":"I Pascual","year":"2022","unstructured":"Pascual I, Hern\u00e1ndez-Vaquero D, Alperi A, Almendarez M, Avanzas P, Kalavrouziotis D, Lorca R, Mesnier J, Arboine L, Mohammadi S, Valle RD, Dumont E, Leon V, De Larochelliere R, Rod\u00e9s-Cabau J, Moris C (2022) Permanent pacemaker reduction using cusp-overlapping projection in TAVR: a propensity score analysis. JACC Cardiovasc Interv 15:150\u2013161","journal-title":"JACC Cardiovasc Interv"},{"key":"2432_CR23","doi-asserted-by":"publisher","unstructured":"Sammour Y, Banerjee K, Kumar A, Lak H, Chawla S, Incognito C, Patel J, Kaur M, Abdelfattah O, Svensson LG, Tuzcu EM, Reed GW, Puri R, Yun J, Krishnaswamy A, Kapadia S (2021) Systematic approach to high implantation of SAPIEN-3 valve achieves a lower rate of conduction abnormalities including pacemaker implantation. Circ: Cardiovasc Interv 14(1):e009407. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.120.009407","DOI":"10.1161\/CIRCINTERVENTIONS.120.009407"},{"key":"2432_CR24","doi-asserted-by":"publisher","unstructured":"Khan AA, Tang GHL, Engstrom K, Khan M, Patel N, Dangas GD, Sharma SK, Kini A (2019) Aortic stenosis with severe asymmetric septal hypertrophy: a novel management strategy to improve TAVR outcomes. JACC: Cardiovasc Interv 12:2228\u20132230.\u00a0https:\/\/doi.org\/10.1016\/j.jcin.2019.06.025","DOI":"10.1016\/j.jcin.2019.06.025"},{"key":"2432_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jaccas.2021.03.028","volume":"3","author":"M Qintar","year":"2021","unstructured":"Qintar M, Villablanca P, Lee J, Wang DD, Frisoli T, O\u2019Neill B, Eng MH, O\u2019Neill WW (2021) Emergency alcohol septal ablation for shock after TAVR: one more option in the toolbox. JACC Case Rep 3:853\u2013858","journal-title":"JACC Case Rep"},{"key":"2432_CR26","doi-asserted-by":"publisher","first-page":"32936","DOI":"10.21037\/acs.2017.07.03","volume":"6","author":"KD Kotkar","year":"2017","unstructured":"Kotkar KD, Said SM, Dearani JA, Schaff HV (2017) Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann Cardiothorac Surg 6:32936\u201332336","journal-title":"Ann Cardiothorac Surg"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02432-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:54:53Z","timestamp":1742201693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02432-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2432"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02432-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a retrospective analysis of anonymized data. Therefore, due to German law, ethical approval is not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent for device implantation and data acquisition.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Martin Beyer received travel compensation from Abbott. Sebastian Ludwig received travel compensation from Edwards Lifesciences Inc. Hermann Reichenspurner received travel compensation and lecture remunerations from Edwards Lifesciences Inc. and Medtronic Inc. Lenard Conradi serves on the advisory board for Medtronic, Abbott, and JenaValve and is consultant for Edwards Lifesciences, Boston Scientific, MicroPort, PiCardia, Neovasc, and MicroInterventions. Moritz Seifert reports personal fees and non-financial support from Abbott Vascular; personal fees from Abiomed; personal fees from AstraZeneca; personal fees from Bayer Healthcare; personal fees from Boehringer Ingelheim; grants, personal fees, and non-financial support from Boston Scientific; personal fees from Bristol-Myers Squibb; personal fees and non-financial support from Edwards Lifesciences; grants and personal fees from Philips; personal fees from Medtronic; personal fees from Amgen; personal fees from Shockwave Medical; personal fees from Daiichi Sankyo; personal fees from Pfizer; personal fees from Siemens Healthineers; and personal fees from Inari Medical. Andreas Sch\u00e4fer received travel compensation from Edwards Lifesciences Inc. and lecture fees from Abbott and Boston Scientific. All other authors declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}